Aviragen Therapeutics to Host Conference Call to Report Third Quarter Fiscal Year 2016 Financial Results on May 5, 2016
April 28 2016 - 4:01PM
Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota
Pharmaceuticals, Inc.) a pharmaceutical company that is developing
the next generation of antivirals, today announced that management
will host a conference call on Thursday, May 5, 2016 at 4:30 p.m.
ET to review the Company’s financial results for the three month
period ended March 31, 2016 and provide an update on recent
corporate developments. The Company will issue a press release
summarizing its financial results the same day, prior to the
conference call.
In order to participate in the conference call,
please dial (877) 312-5422 (domestic) or (253) 237-1122
(international) and refer to conference ID number 1735310. The live
webcast can be accessed under the Investors section of the
Company’s website at www.aviragentherapeutics.com.
About Aviragen Therapeutics,
Inc.
Aviragen Therapeutics is focused on the discovery
and development of the next generation of direct-acting antivirals
to treat infections that have limited therapeutic options and
affect a significant number of patients globally. The Company has
three product candidates in active clinical development: These
include vapendavir, an oral treatment for human rhinovirus upper
(HRV) respiratory infections in moderate-to-severe asthmatics
currently being evaluated in the Phase 2b SPIRITUS trial; BTA585,
an oral fusion protein inhibitor that has received Fast Track
designation by the U.S. FDA, in Phase 2 development for the
treatment and prevention of respiratory syncytial virus (RSV)
infections; and BTA074, a topical antiviral treatment in Phase 2
development for condyloma caused by human papillomavirus types 6
& 11. For additional information about the Company, please
visit www.aviragentherapeutics.com.
Contacts:
Mark Colonnese
Executive Vice President and Chief Financial Officer
Aviragen Therapeutics, Inc.
(678) 221-3381
mcolonnese@aviragentherapeutics.com
Beth DelGiacco
Stern Investor Relations, Inc.
(212) 362-1200
beth@sternir.com
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Apr 2023 to Apr 2024